Wanbury Limited Net Assets

Latest as of September 2025: Rs1.07 Billion INR ≈ $11.60 Million USD

Wanbury Limited net assets. Based on the latest financial reports, Wanbury Limited (WANBURY) has net assets worth Rs1.07 Billion INR (≈ $11.60 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs4.57 Billion ≈ $49.38 Million USD) and total liabilities (Rs3.49 Billion ≈ $37.78 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore WANBURY shareholders equity momentum to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs1.07 Billion
% of Total Assets	23.49%
Annual Growth Rate	-2.77%
5-Year Change	N/A
10-Year Change	N/A
Growth Volatility	69.93

Net Assets of Wanbury Limited (2006–2025)

Net assets of Wanbury Limited from 2006 to 2025. This chart illustrates how Wanbury Limited's net assets have evolved over time, based on quarterly financial data. See WANBURY equity financing ratio to measure how much of total assets are equity-financed.

Annual Net Assets for Wanbury Limited (2006–2025)

The table below shows the annual net assets of Wanbury Limited from 2006 to 2025. For live market cap and overall valuation, see Wanbury Limited market capitalisation.

Year	Net Assets	Change
2025-03-31	Rs592.72 Million ≈ $6.41 Million	+112.13%
2024-03-31	Rs279.41 Million ≈ $3.02 Million	+185.15%
2023-03-31	Rs-328.16 Million ≈ $-3.55 Million	-40.12%
2022-03-31	Rs-234.20 Million ≈ $-2.53 Million	+85.01%
2021-03-31	Rs-1.56 Billion ≈ $-16.90 Million	-8.92%
2020-03-31	Rs-1.43 Billion ≈ $-15.51 Million	+31.45%
2019-03-31	Rs-2.09 Billion ≈ $-22.63 Million	-13.32%
2018-03-31	Rs-1.85 Billion ≈ $-19.97 Million	-20.49%
2017-03-31	Rs-1.53 Billion ≈ $-16.58 Million	+6.10%
2016-03-31	Rs-1.63 Billion ≈ $-17.65 Million	+7.88%
2015-03-31	Rs-1.77 Billion ≈ $-19.16 Million	-7.35%
2014-03-31	Rs-1.65 Billion ≈ $-17.85 Million	-675.06%
2013-03-31	Rs-212.95 Million ≈ $-2.30 Million	-129.95%
2012-03-31	Rs711.13 Million ≈ $7.69 Million	-32.26%
2011-03-31	Rs1.05 Billion ≈ $11.35 Million	-45.45%
2010-03-31	Rs1.92 Billion ≈ $20.81 Million	+21.46%
2009-03-31	Rs1.58 Billion ≈ $17.13 Million	+22.71%
2007-03-31	Rs1.29 Billion ≈ $13.96 Million	+27.66%
2006-03-31	Rs1.01 Billion ≈ $10.94 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Wanbury Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 108352500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Wanbury Limited Net Assets Breakdown (March 2025)

Wanbury Limited net assets breakdown by equity component as of March 2025.

Component	Amount	Percentage
Common Stock	Rs327.70 Million	55.29%
Other Components	Rs1.35 Billion	227.52%
Total Equity	Rs592.72 Million	100.00%

Wanbury Limited Competitors by Market Cap

The table below lists competitors of Wanbury Limited ranked by their market capitalization.

Company	Market Cap
Unitech Electronics Co. Ltd. TW:3652	$72.40 Million
Holland Colours NV AS:HOLCO	$72.42 Million
Metrofile JSE:MFL	$72.47 Million
Recce Pharmaceuticals Ltd AU:RCE	$72.48 Million
Arena Group Holdings Inc NYSE MKT:AREN	$72.36 Million
SKY E&M Co. Ltd KQ:131100	$72.32 Million
Selectquote Inc NYSE:SLQT	$72.30 Million
Mordechai Aviv Taasiot Beniyah 1973 Ltd TA:AVIV	$72.28 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Wanbury Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 279,414,000 to 592,718,000, a change of 313,304,000 (112.1%).
Net income of 305,301,000 contributed positively to equity growth.
Share repurchases of 250,000 reduced equity.
New share issuances of 250,000 increased equity.
Other comprehensive income decreased equity by 179,638,000.
Other factors increased equity by 187,641,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs305.30 Million	+51.51%
Share Repurchases	Rs250.00K	-0.04%
Share Issuances	Rs250.00K	+0.04%
Other Comprehensive Income	Rs-179.64 Million	-30.31%
Other Changes	Rs187.64 Million	+31.66%
Total Change	Rs-	112.13%

Book Value vs Market Value Analysis

This analysis compares Wanbury Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 10.99x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 2.10x to 10.99x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2006-03-31	Rs91.16	Rs191.59	x
2007-03-31	Rs97.01	Rs191.59	x
2009-03-31	Rs102.66	Rs191.59	x
2010-03-31	Rs125.81	Rs191.59	x
2011-03-31	Rs84.22	Rs191.59	x
2012-03-31	Rs30.23	Rs191.59	x
2013-03-31	Rs-27.59	Rs191.59	x
2015-03-31	Rs-97.12	Rs191.59	x
2016-03-31	Rs-94.53	Rs191.59	x
2017-03-31	Rs-73.66	Rs191.59	x
2018-03-31	Rs-77.86	Rs191.59	x
2019-03-31	Rs-88.23	Rs191.59	x
2020-03-31	Rs-59.86	Rs191.59	x
2021-03-31	Rs-62.48	Rs191.59	x
2022-03-31	Rs-7.25	Rs191.59	x
2023-03-31	Rs-1.88	Rs191.59	x
2024-03-31	Rs8.44	Rs191.59	x
2025-03-31	Rs17.43	Rs191.59	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Wanbury Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 51.51%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 5.09%
• Asset Turnover: 1.45x
• Equity Multiplier: 6.98x
Recent ROE (51.51%) is above the historical average (5.61%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2006	10.61%	9.86%	0.56x	1.93x	Rs6.16 Million
2007	16.13%	14.48%	0.45x	2.48x	Rs79.14 Million
2009	-21.31%	-13.23%	0.29x	5.53x	Rs-472.21 Million
2010	4.55%	1.78%	0.59x	4.36x	Rs-100.66 Million
2011	-67.73%	-21.63%	0.51x	6.15x	Rs-961.58 Million
2012	-87.50%	-10.07%	0.48x	18.24x	Rs-433.39 Million
2013	0.00%	-19.00%	0.59x	0.00x	Rs-824.34 Million
2014	0.00%	-19.30%	1.09x	0.00x	Rs-659.68 Million
2015	0.00%	1.28%	0.63x	0.00x	Rs225.98 Million
2016	0.00%	-1.69%	1.11x	0.00x	Rs117.30 Million
2017	0.00%	14.45%	1.04x	0.00x	Rs773.43 Million
2018	0.00%	-8.70%	1.35x	0.00x	Rs-135.40 Million
2019	0.00%	-6.42%	1.35x	0.00x	Rs-39.20 Million
2020	0.00%	17.78%	1.30x	0.00x	Rs788.07 Million
2021	0.00%	-3.26%	1.34x	0.00x	Rs30.19 Million
2022	0.00%	15.94%	1.45x	0.00x	Rs838.16 Million
2023	0.00%	-2.09%	1.64x	0.00x	Rs-97.80 Million
2024	200.26%	9.74%	1.67x	12.29x	Rs531.62 Million
2025	51.51%	5.09%	1.45x	6.98x	Rs246.03 Million

Industry Comparison

This section compares Wanbury Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $18,296,965,823
Average return on equity (ROE) among peers: 13.70%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Wanbury Limited (WANBURY)	Rs1.07 Billion	10.61%	3.26x	$72.39 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$1.38 Billion	2.91%	0.72x	$32.43 Million
Aarti Drugs Limited (AARTIDRUGS)	$13.69 Billion	12.28%	0.88x	$460.26 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$15.58 Billion	12.42%	0.44x	$901.84 Million
Abbott India Limited (ABBOTINDIA)	$20.09 Billion	22.42%	0.46x	$5.93 Billion
Ajanta Pharma Limited (AJANTPHARM)	$37.90 Billion	24.28%	0.32x	$4.49 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$30.64 Billion	11.04%	0.34x	$1.26 Billion
Alkem Laboratories Limited (ALKEM)	$12.05 Billion	19.50%	0.29x	$6.77 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$949.51 Million	15.88%	0.30x	$155.76 Million
Alembic Pharmaceuticals Limited (APLLTD)	$27.18 Billion	21.50%	0.76x	$1.71 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$23.50 Billion	-5.26%	1.65x	$10.54 Billion

About Wanbury Limited

NSE:WANBURY India Drug Manufacturers - Specialty & Generic

Market Cap

$72.39 Million

Rs6.69 Billion INR

Market Cap Rank

#20280 Global

#1117 in India

Share Price

Rs191.59

Change (1 day)

+0.56%

52-Week Range

Rs163.34 - Rs344.75

All Time High

Rs344.75